ClinicalTrials.gg
RecruitingNCT07685483Updated Jul 6, 2026

Dramatherapy for Psychological and Social Well-Being in Obesity and Bariatric Care

An interventional study of Adapted Physical Activity and Dramatherapy in Obesity (Disorder), Obesity & Overweight and Eating Disorders, sponsored by Universite du Littoral Cote d'Opale. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-06.

Sponsored by Universite du Littoral Cote d'Opale · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jun 2026; still recruiting 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
250
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 476 studies in Obesity with a site in France — 112 open to participants now, 128 under way, 25 of them phase 3. Obesity · France.

Planned enrollment
90th of 355
250 · median 80
Started
2026
with 29 others
No phase
259 of 476
64 open now
Primary completion
2029-05
later than 106 of 127 live
Registered
461st of 476
by date

Among the 476 studies in Obesity with a site in France, this one is the 90th largest by planned enrollment of the 355 interventional ones that give a count, is one of 30 that started in 2026, is one of 259 with no phase, reaches primary completion later than 106 of the 127 other live ones, and was the 461st registered.

Obesity

11,564 studies on the registry are indexed under Obesity; 2,063 are open to participants now.

Browse Obesity studies →

Open to participants now

112 of the 476 studies in Obesity with a site in France are open now. Recruiting first, the newest first:

106 more — sign in →

All 112 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 1,352 Obesity studies recruiting now, 382 (28%) set no upper age limit and 867 (64%) stop at 75 or younger; 169 take children under 18; 491 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 476 studies in Obesity with a site in France, or all of them as a file.
02

Study summary

Obesity is currently a major public health challenge in France, particularly in the Hauts-de-France region, where prevalence exceeds 20% of the adult population. Bariatric surgery has considerably increased over the last two decades and is now recognized as an effective therapeutic option within a multidisciplinary care pathway. However, many patients continue to experience difficulties related to body image, emotional regulation, problematic eating behaviors, and long-term adherence to adapted physical activity (APA), which may limit the sustainability of treatment benefits. International literature highlights the importance of integrating psychological and psychosocial support alongside medical, nutritional, and physical interventions.

This monocentric randomized controlled trial aims to evaluate the effects of adding dramatherapy (DT) to a standardized APA program in adult patients with obesity enrolled in medical or bariatric care pathways at the Institut de l'Obésité of Clinique ELSAN Saint-Omer (France). Participants will be randomized to receive either standard APA alone or APA combined with DT. The intervention is designed to improve emotional expression, body perception, self-confidence, psychosocial well-being, and long-term adherence to care. Dramatherapy sessions will include theatrical expression, role play, improvisation, relaxation, and body-oriented creative exercises adapted to patients with obesity.

The primary objective is to evaluate the effect of DT on quality of life at the end of care, compared with APA alone, using the French version of the EQVOD questionnaire. Secondary objectives include the evaluation of eating behaviors and problematic eating regulation (TFEQ-R18, SCOFF), body image and body-related quality of life (BIQLI), self-efficacy (GSES), anxiety and depressive symptoms (BDI-II), adherence to APA programs, and anthropometric parameters such as body mass index, abdominal circumference, and body composition. Assessments will be conducted at baseline, at the end of the intervention, and at 6- and 12-month follow-up.

The study also includes a complementary qualitative component based on semi-structured interviews, ethnographic observation, body mapping, and identity boxes in order to explore patients' subjective experiences, psychosocial trajectories, and perceived impact of the intervention. Quantitative and qualitative data will be analyzed using a mixed-methods approach. A total of 250 participants are expected to be included. This study seeks to provide evidence regarding the potential added value of integrating dramatherapy into obesity and bariatric care pathways.

Read the detailed description

Obesity is a major public health concern worldwide and represents a particularly important challenge in France and in the Hauts-de-France region, where prevalence rates exceed 20% of the adult population. Obesity is associated with increased morbidity and mortality, including cardiovascular diseases, type 2 diabetes, respiratory disorders, musculoskeletal conditions, and psychological distress. In this context, bariatric surgery has become an increasingly common therapeutic option for patients with severe obesity and is currently integrated into multidisciplinary care pathways including medical follow-up, nutritional counseling, psychological support, and adapted physical activity (APA).

Despite the recognized effectiveness of bariatric surgery and APA programs, many patients continue to experience difficulties related to body image, emotional regulation, self-esteem, problematic eating behaviors, and long-term adherence to lifestyle changes. These psychosocial dimensions may negatively affect the sustainability of treatment benefits and contribute to weight regain or reduced quality of life over time. International literature therefore emphasizes the importance of comprehensive interventions integrating psychological and psychosocial support alongside standard medical and nutritional care.

Adapted physical activity is recognized as an essential component of obesity and bariatric care. APA contributes to improvements in physical condition, body composition, psychological well-being, and quality of life. However, long-term adherence to physical activity programs remains challenging for many patients, particularly because of stigma, altered body perception, anxiety related to movement, and low self-confidence.

Dramatherapy (DT) is a creative therapeutic approach using theatrical tools such as role play, improvisation, embodiment, storytelling, symbolic expression, and group interaction to facilitate emotional expression, body awareness, psychosocial adjustment, and identity reconstruction. Although dramatherapy and related creative arts therapies have shown promising effects in mental health and psychosocial rehabilitation, their integration into obesity and bariatric care pathways remains largely underexplored. To date, no randomized controlled trial has systematically evaluated the effects of combining dramatherapy with adapted physical activity in patients with obesity enrolled in medical or bariatric care pathways.

The present study is a monocentric randomized controlled trial conducted at the Institut de l'Obésité of Clinique ELSAN Saint-Omer (France), in collaboration with the URePSSS research laboratory (ULR 7369, Université du Littoral Côte d'Opale). The study aims to evaluate the effects of adding dramatherapy to a standardized APA program in adult patients with obesity participating in either a medical obesity care pathway or a bariatric surgery pathway.

Participants will be recruited during routine consultations within the obesity care program. Eligible participants are adults aged 18 years or older with:

  • BMI ≥ 40 kg/m²;
  • or BMI ≥ 35 kg/m² with obesity-related comorbidities;
  • or BMI ≥ 30 kg/m² associated with eating disorders or problematic eating behaviors.

Participants must be enrolled in a medical or bariatric care pathway including APA, be able to participate in the study procedures, and provide written informed consent. Exclusion criteria include major medical contraindications to APA or group participation, severe unstable psychiatric disorders, severe cognitive impairment, unstable medical treatment significantly affecting weight or mental health, inability to comply with follow-up procedures, or inability to provide informed consent.

The study follows a randomized controlled design with two parallel groups:

  1. Standardized adapted physical activity alone (control group);
  2. Standardized adapted physical activity combined with dramatherapy (experimental group).

Randomization will be stratified according to care pathway type (medical versus bariatric). The study uses a two-stage randomized consent design inspired by Zelen methodology. Participants initially consent to participation and randomization, while a second specific consent is requested only from patients allocated to the additional dramatherapy intervention.

The APA program consists of 12 supervised sessions over 6 weeks, delivered by qualified APA professionals. Sessions include cardiovascular exercises, muscle strengthening, and progressive movement activities adapted to the physical capacities of patients with obesity.

The dramatherapy intervention is delivered by a qualified and experienced dramatherapist. It consists of six weekly group sessions lasting approximately 90 minutes each. The intervention uses theatrical expression, role play, improvisation, breathing exercises, body-oriented activities, symbolic work, and collective interaction to improve body awareness, emotional regulation, self-esteem, social interaction, and engagement in care. For patients enrolled in bariatric pathways, dramatherapy may be delivered during pre-operative and/or post-operative phases depending on the timing of inclusion.

The primary objective is to evaluate the effect of adding dramatherapy to APA on quality of life at the end of care compared with APA alone. Quality of life will be assessed using the French version of the EQVOD questionnaire.

Secondary objectives include evaluating:

  • eating behaviors and problematic eating regulation using the TFEQ-R18 and SCOFF questionnaires;
  • body image and body-related quality of life using the BIQLI;
  • self-efficacy using the General Self-Efficacy Scale (GSES);
  • anxiety and depressive symptoms using the Beck Depression Inventory-II (BDI-II);
  • adherence and participation in APA programs;
  • anthropometric outcomes including body mass index, abdominal circumference, and body composition.

Assessments will be performed at several time points:

  • baseline/pre-care assessment;
  • beginning of care;
  • end of care;
  • 6-month follow-up;
  • 12-month follow-up.

The study also includes a complementary qualitative and ethnographic component intended to enrich interpretation of quantitative findings and explore the subjective experience of participants. Semi-structured interviews, participant observation, body mapping techniques, and identity boxes will be used to investigate body perception, emotional experiences, psychosocial trajectories, relationship to food and movement, and perceptions of dramatherapy and obesity care pathways.

Quantitative analyses will include descriptive statistics, repeated-measures analyses, mixed linear models, subgroup analyses, and exploratory multivariate analyses. Qualitative data will be analyzed using thematic content analysis and triangulated with quantitative findings within a mixed-methods framework.

The target sample size is 250 participants. This sample size was determined to ensure adequate statistical power for the primary outcome analysis while accounting for potential attrition during long-term follow-up.

The expected duration of inclusion is approximately 1 year and 6 weeks. Individual participation lasts 6 weeks for the intervention phase, with follow-up assessments extending to 12 months. The total duration of the research project is estimated at 36 months.

This study aims to provide new evidence regarding the integration of creative therapeutic approaches into obesity and bariatric care pathways and to evaluate whether combining dramatherapy with adapted physical activity may improve psychological well-being, body-related outcomes, adherence to care, and quality of life in patients with obesity.

03

Conditions studied

  • Obesity (Disorder)
  • Obesity & Overweight
  • Eating Disorders
  • Bariatric Surgery

Keywords

  • Obesity
  • Eating Disorders
  • Bariatric Surgery
  • Dramatherapy
  • Art Therapy
  • Adapted Physical Activity
  • Body image
  • Quality of life
  • Psychosocial Well-Being
  • Psychosocial intervention
  • Body Mapping
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18 years or older.
  • (BMI) ≥ 40 kg/m², or BMI ≥ 35 kg/m² with obesity-related comorbidities, or BMI ≥ 30 kg/m² with associated eating disorders or problematic eating behaviors.
  • Enrollment in a medical or bariatric care pathway at the Institut de l'Obésité, Clinique ELSAN Saint-Omer, including a therapeutic education program with adapted physical activity.
  • Availability and willingness to complete the planned study procedures and follow-up assessments.
  • Written provided after complete information about the study.
  • Affiliation to a social security system.

Exclusion criteria

Exclusion Criteria:

  • Major medical to adapted physical activity or group sessions, including unstable cardiovascular disease or severe non-compensable locomotor limitations.
  • Severe psychiatric disorders or severe unstable eating disorders contraindicating bariatric surgery or preventing adequate participation in group sessions.
  • Major cognitive impairment or neuropsychological disorders preventing understanding of instructions or completion of assessments.
  • Unstable medical treatment or recent therapeutic modification likely to significantly affect body weight, fatigability, or mental health.
  • Inability to complete the full study protocol, including prolonged unavailability or planned relocation outside the region.
  • Refusal or inability to provide .
  • Major logistical barriers preventing access to the intervention site without feasible alternative arrangements.
  • Participation in a structured adapted physical activity program within the 3 months preceding inclusion.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
250 participants (estimated)

Study arms

  • Active comparator
    Adapted Physical Activity

    Participants allocated to the control group will receive the standard adapted physical activity (APA) program routinely implemented within the obesity care pathway. The intervention consists of 12 supervised sessions over 6 weeks, including cardiovascular exercises, muscle strengthening, and progressive movement activities adapted to the physical capacities and clinical condition of patients with obesity. Sessions are delivered by qualified APA professionals as part of the multidisciplinary obesity and bariatric care program.

    Behavioral: Adapted Physical Activity

  • Other
    Adapted Physical Activity + Dramatherapy

    Participants allocated to the experimental group will receive the standard adapted physical activity (APA) program combined with a complementary dramatherapy intervention. In addition to the 12 supervised APA sessions delivered over 6 weeks, participants will take part in weekly group dramatherapy sessions led by a qualified art therapist. The intervention includes theatrical expression, role play, improvisation, breathing and relaxation exercises, body-oriented creative activities, and collective interaction aimed at improving emotional expression, body image, self-confidence, psychosocial well-being, and long-term adherence to care.

    Behavioral: Adapted Physical Activity · Behavioral: Dramatherapy

Interventions

  • BehavioralAdapted Physical Activity

    Standardized supervised adapted physical activity program including cardiovascular exercises, muscle strengthening, and progressive movement activities adapted to patients with obesity. The program consists of 12 sessions delivered over 6 weeks by qualified APA professionals.

  • BehavioralDramatherapy

    Group dramatherapy intervention including theatrical expression, role play, improvisation, breathing and relaxation exercises, body-oriented creative activities, and collective interaction aimed at improving emotional expression, body image, self-confidence, and psychosocial well-being.

06

What researchers measure

Primary outcomes

  1. Change in Quality of Life Assessed by the Échelle Qualité de Vie, Obésité et Diététique / Quality of Life, Obesity and Dietetics Global Score

    Quality of life will be assessed using the global score of the French version of the Échelle Qualité de Vie, Obésité et Diététique (EQVOD), also known as the Quality of Life, Obesity and Dietetics (QOLOD) rating scale. The EQVOD/QOLOD is an obesity-specific quality-of-life questionnaire. Scores are transformed to a 0-100 scale, with higher scores indicating better health-related quality of life. The primary endpoint is the between-group difference in EQVOD/QOLOD global score at the end of care, adjusted for baseline values. In the absence of a validated minimal clinically important difference for this population, a distribution-based approach will be used, considering a difference of 0.5 standard deviation in the global score as clinically meaningful.

    Time frame: Baseline and end of care 6 weeks, 6 months, 12 months

Secondary outcomes

  1. Change in Eating Disorder Screening Score Assessed by the SCOFF Questionnaire

    Eating disorder screening indicators will be assessed using the Sick, Control, One Stone, Fat, Food questionnaire (SCOFF). The SCOFF total score ranges from 0 to 5, with higher scores indicating more eating disorder screening indicators and a higher risk of eating disorders or problematic eating behaviors. A score of 2 or more is commonly considered indicative of possible eating disorder risk requiring further clinical assessment.

    Time frame: Baseline, end of care approximately 6 weeks, 6 months, and 12 months

  2. Change in Eating Behaviors Assessed by the Three-Factor Eating Questionnaire-Revised 18-Item Version

    Eating behaviors will be assessed using the Three-Factor Eating Questionnaire-Revised 18-item version (TFEQ-R18). The TFEQ-R18 assesses three dimensions of eating behavior: cognitive restraint, uncontrolled eating, and emotional eating. Each subscale score is transformed to a 0-100 scale. Higher scores indicate a higher level of the corresponding eating behavior: greater cognitive restraint, greater uncontrolled eating, or greater emotional eating.

    Time frame: Baseline, end of care (6 weeks), 6 months, and 12 months

  3. Change in Body Image-Related Quality of Life Assessed by the Body Image Quality of Life Inventory

    Body image-related quality of life will be assessed using the Body Image Quality of Life Inventory (BIQLI). The BIQLI is a 19-item self-report questionnaire assessing the impact of body image on different areas of daily life and psychosocial well-being. Each item is scored from -3 to +3. The global mean score ranges from -3 to +3, with higher scores indicating a more positive impact of body image on quality of life and therefore a better outcome.

    Time frame: Baseline, end of care (6 weeks), 6 months, and 12 months

  4. Change in Self-Efficacy Assessed by the General Self-Efficacy Scale

    Self-efficacy will be assessed using the General Self-Efficacy Scale (GSES). The GSES is a 10-item self-report questionnaire evaluating participants' perceived ability to cope with difficult situations and maintain behavioral changes related to health, physical activity, and eating behaviors. Each item is scored from 1 to 4, and the total score ranges from 10 to 40. Higher scores indicate higher perceived self-efficacy and therefore a better outcome.

    Time frame: Baseline, end of care (6 weeks), 6 months, and 12 months

  5. Change in Depressive Symptoms Assessed by the Beck Depression Inventory-Second Edition

    Depressive symptoms will be assessed using the Beck Depression Inventory-Second Edition (BDI-II). The BDI-II is a 21-item self-report questionnaire evaluating the severity of depressive symptoms. Each item is scored from 0 to 3, and the total score ranges from 0 to 63. Higher scores indicate greater depressive symptom severity and therefore a worse outcome.

    Time frame: Baseline, end of care (6 weeks), 6 months, and 12 months

  6. Adherence to Adapted Physical Activity Assessed by Attendance Rate

    Adherence to the adapted physical activity (APA) program will be assessed using attendance records. The attendance rate will be calculated as the percentage of scheduled APA sessions attended by each participant. The score ranges from 0% to 100%, with higher percentages indicating greater adherence to the APA program and therefore a better outcome.

    Time frame: During the 6 week period

  7. Change in Body Mass Index

    Body mass index (BMI) will be calculated as body weight in kilograms divided by height in meters squared and reported in kg/m². Lower BMI values over time indicate a reduction in body mass index and generally a better outcome in the context of obesity care.

    Time frame: Baseline, end of care (6 weeks), 6 months, and 12 months

  8. Change in Body Weight

    Body weight will be measured using standardized clinical procedures and reported in kilograms. Lower body weight values over time indicate weight reduction and generally a better outcome in the context of obesity care.

    Time frame: Baseline, end of care approximately 6 weeks, 6 months, and 12 months

  9. Change in Abdominal Circumference

    Abdominal circumference will be measured using standardized clinical procedures and reported in centimeters. Lower abdominal circumference values over time indicate a reduction in abdominal adiposity and generally a better outcome in the context of obesity care.

    Time frame: Baseline, end of care approximately 6 weeks, 6 months, and 12 months

  10. Change in Body Composition Assessed by Bioimpedance Analysis

    Body composition will be assessed using bioimpedance analysis. The main reported parameter will be body fat percentage, expressed as a percentage of total body weight. Lower body fat percentage values over time indicate a reduction in body fat and generally a better outcome in the context of obesity care.

    Time frame: Baseline, end of care approximately 6 weeks, 6 months, and 12 months

Other outcomes

  1. Semi-Structured Interview Themes and Theme Frequencies Related to Treatment Experience and Perceived Change

    Participants will take part in semi-structured interviews exploring their lived experiences of obesity, body image, eating behaviors, psychosocial well-being, and engagement with adapted physical activity and dramatherapy interventions. Interviews will be audio-recorded, transcribed, and analyzed using thematic content analysis in order to identify psychosocial and behavioral factors associated with treatment experience and perceived changes over time.

    Time frame: Baseline, end of care (6 weeks), 6 months, and 12 months

  2. Ethnographic Observation Themes and Theme Frequencies Related to Engagement and Group Dynamics

    Ethnographic observation will be conducted during adapted physical activity and dramatherapy sessions to explore participants' engagement, emotional expression, social interaction, body-related behaviors, and group dynamics. Observations will be documented in structured field notes and analyzed thematically. This qualitative outcome will identify themes related to the psychosocial experience of the interventions and will not be reported as a numerical score.

    Time frame: From baseline through study completion, approximately 12 months

  3. Participant-Reported Body Mapping Themes Related to Body Perception and Emotional Experience

    Body mapping techniques will be used as creative and visual elicitation tools to explore participants' body perception, emotional experiences, relationship to obesity, and perceived bodily changes throughout the care pathway. Visual productions and associated narratives will be analyzed using thematic and interpretative approaches.

    Time frame: Baseline, end of care (6 weeks), 6 months, and 12 months

  4. Identity Box Themes and Theme Frequencies Related to Psychosocial Identity and Perceived Change

    Identity boxes will be used as a qualitative elicitation tool to explore participants' experiences of body image, obesity, eating behaviors, psychosocial identity, and therapeutic trajectory. Participants will be invited to select, bring, or create personal objects that support narrative expression during interviews. The objects and associated narratives will be analyzed together as an integrated qualitative dataset using thematic analysis. This qualitative outcome will identify themes related to meaning-making processes and psychosocial changes over time and will not be reported as a numerical score.

    Time frame: Baseline, end of care approximately 6 weeks, 6 months, and 12 months

07

Study locations

1 of 1 sites recruiting
  • Clinique Elsan de Saint Omer
    Blendecques, Hauts-de-France 62575, France
    Recruiting
08

References and documents

Individual participant data

Plan to share: No — This study collects sensitive psychosocial, behavioral, and qualitative data related to obesity, eating behaviors, mental health, and body image. Individual participant data will not be publicly shared in order to protect participant confidentiality and in accordance with French data protection regulations (CNIL/MR001 framework).

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2026 (actual). Primary completion is estimated for May 2029, 35 months after the start.

Of 3,697 non-industry interventional studies with no phase under Obesity, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 43. This study's planned 35 months is above that.

Counting every sponsor, half of 3,861 studies reached it within 22 months; a quarter within 9 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
May 27, 2026
First posted
Jul 6, 2026
StartActual
Jun 30, 2026
Primary completionEst.
May 2029
CompletionEst.
May 2029
Last update
Jul 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07685483
Lead sponsor
Universite du Littoral Cote d'Opale
Collaborators
ELSAN Clinic in Saint Omer, France
Responsible party
Sponsor
First posted
Jul 6, 2026
Start date
Jun 30, 2026
Primary completion
May 2029 (estimated)
Completion
May 2029 (estimated)
Last update
Jul 6, 2026

Study contacts

Alessandro Porrovecchio, PhD HDR
Contact
alessandro.porrovecchio@univ-littoral.fr
0033647120423
Suzanne Vanachter, PhD Student
Contact
vanachter.s@gmail.com
0033672481842
Alessandro Porrrovecchio, PhD HDR
principal investigator · Université du Littoral Cote d'Opale
Morgane Carton
principal investigator · ELSAN Clinic in Saint Omer
Ariane Martinez, Full Professor
principal investigator · Lille University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion